Qiji Investment
齐济投资
Qiji Investment (齐济投资) is a Chinese venture capital fund that appears as a co-investor alongside larger institutions in biotech and medtech deals. It followed Gaorong Capital in an angel-plus round for Shenzhen-based brain-computer interface startup WeLing Medical in late 2023 , and joined a roughly RMB 400 million Series B+ for Chengdu drug developer Zenitar in August 2025 alongside Qiming Venture Partners, Gaorong, Jifeng Capital, 5Y Capital and others . elsewhere's corpus does not contain additional detail on its vintage, AUM or founding team.
AI-generated — may contain errors, please verify.
Coverage
5Y News | Zai Ling Bio Completes Nearly RMB 400 Million Series B+ Round
Accelerating the buildout of an innovative drug pipeline built on differentiated molecular scaffolds and novel targets, with a commitment to addressing unmet clinical needs.
Zenitar Closes Nearly RMB 400 Million Series B+ Round, Multiple Global First-in-Class Drugs Enter Pivotal Clinical Trials
Structural Biology and AI-Driven Innovative Drug Discovery and Development
WeLing Medical Completes Angel Plus Round to Advance Fully Implantable Medical-Grade Brain-Computer Interface System
Accelerating the clinical translation of brain-computer interface technology.
